Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P A Davis

Showing results (111-120 of 130) with videos related to

Pageof 13
Sort By:
Annals of Internal Medicine|October 1, 1993
A linoleate-enriched cheese product reduces low-density lipoprotein in moderately hypercholesterolemic adultsP A Davis, J F Platon, M E Gershwin, et al.
Contributions to Nephrology|January 1, 1997
Constitutive nitric oxide synthase gene expression in Bartter's and Gitelman's syndrome and its relationship to their vascular hyporesponsivenessL Calò, M C Bordin, P A Davis, et al.
Kidney International|September 5, 2001
Abnormalities of Gq-mediated cell signaling in Bartter and Gitelman syndromesL Calò, G Ceolotto, M Milani, et al.
Blood|March 1, 1994
Flexible granulocyte colony-stimulating factor dosing in ovarian cancer patients who receive dose-intense taxol therapyC J Link, A Bicher, E C Kohn, et al.
Clinical Nephrology|December 2, 2004
Vitamin E-coated dialyzers reduce oxidative stress related proteins and markers in hemodialysis--a molecular biological approachL A Calò, A Naso, E Pagnin, et al.
Maturitas|October 23, 2015
Estimating cut points: A simple method for new wearablesA Hickey, J Newham, M M Slawinska, et al.
The American Journal of Clinical Nutrition|October 15, 1998
Reduced oxidative susceptibility of LDL from patients participating in an intensive atherosclerosis treatment programE J Parks, J B German, P A Davis, et al.
Journal of Endocrinological Investigation|July 17, 2009
High angiotensin II state without cardiac remodeling (Bartter's and Gitelman's syndromes): are angiotensin II type 2 receptors involved?L A Calò, R Montisci, R Scognamiglio, et al.
Review (Federation of American Health Systems)|April 9, 1989
Managed care--a symposiumA Miller, G P Herman, P A Davis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1997
Phase I trial of micronized formulation carboxyamidotriazole in patients with refractory solid tumors: pharmacokinetics, clinical outcome, and comparison of formulationsE C Kohn, W D Figg, G A Sarosy, et al.
Pageof 13

Showing results (111-120 of 130) with videos related to

Sort By:
Pageof 13
Annals of Internal Medicine|October 1, 1993
A linoleate-enriched cheese product reduces low-density lipoprotein in moderately hypercholesterolemic adultsP A Davis, J F Platon, M E Gershwin, et al.
Contributions to Nephrology|January 1, 1997
Constitutive nitric oxide synthase gene expression in Bartter's and Gitelman's syndrome and its relationship to their vascular hyporesponsivenessL Calò, M C Bordin, P A Davis, et al.
Kidney International|September 5, 2001
Abnormalities of Gq-mediated cell signaling in Bartter and Gitelman syndromesL Calò, G Ceolotto, M Milani, et al.
Blood|March 1, 1994
Flexible granulocyte colony-stimulating factor dosing in ovarian cancer patients who receive dose-intense taxol therapyC J Link, A Bicher, E C Kohn, et al.
Clinical Nephrology|December 2, 2004
Vitamin E-coated dialyzers reduce oxidative stress related proteins and markers in hemodialysis--a molecular biological approachL A Calò, A Naso, E Pagnin, et al.
Maturitas|October 23, 2015
Estimating cut points: A simple method for new wearablesA Hickey, J Newham, M M Slawinska, et al.
The American Journal of Clinical Nutrition|October 15, 1998
Reduced oxidative susceptibility of LDL from patients participating in an intensive atherosclerosis treatment programE J Parks, J B German, P A Davis, et al.
Journal of Endocrinological Investigation|July 17, 2009
High angiotensin II state without cardiac remodeling (Bartter's and Gitelman's syndromes): are angiotensin II type 2 receptors involved?L A Calò, R Montisci, R Scognamiglio, et al.
Review (Federation of American Health Systems)|April 9, 1989
Managed care--a symposiumA Miller, G P Herman, P A Davis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1997
Phase I trial of micronized formulation carboxyamidotriazole in patients with refractory solid tumors: pharmacokinetics, clinical outcome, and comparison of formulationsE C Kohn, W D Figg, G A Sarosy, et al.
Pageof 13